IMPORTANCE Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH).
N on-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used as alternatives to warfarin to prevent thromboembolic complications in high-risk patients with atrial fibrillation. 1, 2 Although NOACs have a more favorable safety profile than warfarin, the annual risk of intracerebral hemorrhage (ICH) among NOAC-treated patients is 0.5%. [3] [4] [5] [6] Prior studies regarding the outcomes of ICH among patients taking NOAC therapy are limited in size and scope. [7] [8] [9] With the rapid adoption of NOACs in clinical practice, there is a need to better understand the outcomes among patients who develop an ICH with prior NOAC therapy compared with those experiencing ICH either with prior warfarin therapy or among those without prior oral anticoagulation. The goals of the study were to evaluate the characteristics and clinical outcomes in patients who experienced an ICH with preceding use of NOACs compared with no oral anticoagulants (OACs) and warfarin, and to determine the incremental risk of mortality and disability associated with the concomitant prior use of OACs and antiplatelet therapy according to the type of anticoagulants.
Methods

Data Source
This retrospective cohort study used data from the American Heart Association/American Stroke Association Get With The Guidelines-Stroke (GTWG-Stroke), which is an ongoing, voluntary, continuous registry sponsored by the American Heart Association/American Stroke Association. Details of GWTG-Stroke registry data collection and variable definitions have been previously described. 10 Standardized data collection includes patient demographic information, medical history, diagnostic testing, brain imaging, in-hospital treatment, and outcomes. The validity and reliability of data collection in GWTG-Stroke have been reported in previous research. 11 Quintiles serves as the data collection and coordination center for GWTG-Stroke. The Duke Clinical Research Institute serves as the data analysis center and has an agreement to analyze the aggregate deidentified data for research purposes. Each participating hospital received either human research approval to enroll patients without individual patient consent under the Common Rule or a waiver of authorization and exemption from subsequent review by their institutional review board. This study was approved by the institutional review board of Duke University.
Study Population
All patients with a diagnosis of ICH were identified in the GWTG-Stroke registry database between October 2013 and December 2016. Preceding use of OACs or antiplatelet therapy was recorded as part of routine care and defined as any use within 7 days prior to hospital arrival. For the purpose of the study, preceding anticoagulation treatments were categorized into 3 mutually exclusive groups: (1) warfarin; (2) NOACs; and (3) no OACs ( Figure 1 ). NOACs were defined as the preceding use of dabigatran, rivaroxaban, apixaban, or edoxaban. Patients were excluded from the analysis if they were taking 2 or more anticoagulant agents (both NOACs and warfarin, or NOAC or warfarin with other anticoagulants such as heparin and low-molecular-weight heparin). Antiplatelet treatments were classified into 3 categories: (1) no antiplatelet therapy, (2) single antiplatelet therapy (SAPT); and (3) dual antiplatelet therapy (DAPT) (Figure 1 ). SAPT was defined as any one of the following antiplatelet agents prior to ICH: aspirin, clopidogrel, ticlopidine, prasugrel, or ticagrelor. DAPT was defined as aspirin/dipyridamole, aspirin plus aspirin/dipyridamole, aspirin plus clopidogrel, ticlopidine, prasugrel, or ticagrelor. Patients who were not in any of these 3 antiplatelet groups were excluded from the analysis.
Outcome Measures
The primary outcome was in-hospital mortality (yes or no). The exploratory outcomes included discharge disposition (home vs other), in-hospital mortality or discharge to hospice, ambulatory status at discharge (able to ambulate independently vs not), and modified Rankin Scale (mRS) score at discharge (range, 0 [no symptoms] to 6 [death] ). Patients with an mRS score of 0 or 1 were classified as having excellent recovery, and those with an mRS score of 0 to 2 were classified as having functional independence.
Statistical Analysis
Baseline characteristics were compared across 3 preceding anticoagulation treatment groups. Medians with interquartile ranges were calculated for continuous variables in each group and compared using a Kruskal-Wallis test. Categorical variables were reported as counts and percentages, and differences among groups were assessed using the χ 2 test.
Multivariable logistic regression models were performed to assess the relationship between preceding anticoagulation therapies with each clinical outcome. These analyses adjusted for baseline demographic and clinical variables prior to the index ICH event including demographics (age, sex, and race/ethnicity [black, Hispanic, Asian, and other vs white: admission staff, medical staff, or both recorded the patient's self-reported race/ethnicity, usually during registration; prior studies have suggested differences in outcomes from intracerebral hemorrhage related to race/ethnicity]), insurance, medical history (atrial fibrillation/flutter, coronary artery disease or prior myocardial infarction, carotid stenosis, diabetes, peripheral vascular disease, hypertension, smoking, dyslipidemia, prior stroke or transient ischemic attack, heart failure, drug or alcohol abuse, obesity or overweight, and renal insufficiency), arrival and admission information (emergency medical services arrival and transfer-in [vs private transportation] and arrived off hours), medications at admission (antihypertensive, lipid-lowering, and diabetic agents), and hospital characteristics (region, rural vs urban, teaching hospital, number of beds, and certified primary stroke center). All continuous variables were tested for linearity and included in the model as a linear variable except for age. A nonlinear relationship exists between in-hospital death and age; therefore, splines with a cutoff point of age 70 years were used in the model. The preceding anticoagulation treatment was included as an independent variable, with no OACs or warfarin as the reference groups.
As a sensitivity analysis, the same analyses were replicated in patients without preceding use of any antiplatelet therapy. Furthermore, sensitivity analyses were also performed in patients with a National Institutes of Health Stroke Scale (NIHSS) score on admission, with the model including NIHSS score along with other covariates. NIHSS was used as a measure of stroke severity (range, 0-42, with a higher score indicating greater stroke severity), but it was not included in the main model because a higher NIHSS score could be the result of hematoma expansion caused by NOACs or OACs and controversies existed about whether NIHSS should be included in the model. The generalized estimation equation (GEE) modeling approach was used to account for withinhospital clustering of patients. In addition, the GEE approach using normal distribution with identity link was used for estimating unadjusted and adjusted risk differences. 12, 13 To evaluate the differences in the incremental risk of mortality and disability with the concomitant prior antiplatelet therapy according to underlying OAC, multivariable logistic regression models with GEE were performed in each OAC group, respectively, with antiplatelet treatment category (no antiplatelet, SAPT, or DAPT) as the independent variable and no antiplatelet as the reference group.
As a sensitivity analysis, multivariable logistic regression models with GEE were performed to compare the in-hospital mortality rate among patients with preceding use of NOACs with that among patients with preceding use of warfarin in the therapeutic range. Additionally, the association of international normalized ratio (INR) level and outcomes was also evaluated among patients with prior use of warfarin. For these additional analyses, patients with prior use of warfarin were classified into 3 categories based on admission INR level: (1) subtherapeutic, defined as INR less than 2; (2) therapeutic, with INR ranging from 2 to 3; and (3) supratherapeutic defined as INR greater than 3.
All variables had less than 2% missing data except for insurance (7.4%) and preadmission medications (18.1% for antihypertensive and 21.8% for diabetic medications). Details of missing values can be found in eTable 1 in the Supplement. To account for missing data, single imputation was used for each variable: men for sex, non-Hispanic white for race/ethnicity, private transportation for emergency medical services arrival and transfer in, and "no" for other. All statistical analyses were performed by the Duke Clinical Research Institute using SAS software version 9.4 (SAS Institute Inc). All P values were 2-sided. For the primary outcome (in-hospital mortality), the Bonferroni correction approach was used to account for multiple comparisons, and P < .025 was considered statistically significant and 97.5% CIs instead of 95% CIs were reported. For other outcomes, P < .05 was considered statistically significant and 95% CIs were reported. Figure 1 ). Baseline characteristics by OAC type are shown in Table 1 .
Patients with preceding use of warfarin or NOACs were more likely to be older, white, and have a higher prevalence of atrial fibrillation, prior stroke or transient ischemic attack, and atherosclerotic comorbidities (eg, coronary artery disease, diabetes, hypertension, dyslipidemia, and heart failure). The severity of ICH at admission, as measured by NIHSS, was not significantly different across the 3 groups (median [interquartile range]: 9 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , 8 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and 8 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] for warfarin, NOACs, and no OACs, respectively). When directly comparing patients with preceding use of warfarin with those with preceding use of NOACs, the baseline characteristics were not significantly different except for a higher prevalence of renal disease in patients with prior use of warfarin and a higher prevalence of atrial fibrillation in patients with prior use of NOACs.
Preceding Anticoagulation Treatment and Outcome Measures
The unadjusted in-hospital mortality rates were 32.6% for prior use of warfarin, 26.5% for prior use of NOACs, and 22.5% for no preceding use of OACs. Table 2) . Ambulatory and functional outcomes were not significantly different between patients with prior use of NOACs vs no prior use of OACs, whereas patients with prior use of NOACs were more likely to be discharged home and have better functional outcomes at discharge than those with prior use of warfarin (Table 2) . These findings were consistent when confined to patients without preceding use of any antiplatelet agents (n = 95 943) (eTable 2 in the Supplement). In addition, sensitivity analyses in patients with NIHSS on admission (n = 90 223) also were consistent with the main findings even after the further adjustment with NIHSS score (eTable 3 in the Supplement).
Incremental Risk of Mortality and Disability With Concomitant Anticoagulant and Antiplatelet Therapy
Baseline characteristics by number of antiplatelet agents are shown in eTable 4 in the Supplement. Compared with patients without prior use of antiplatelet therapy, patients with prior use of antiplatelet therapy were older and had higher burden of atherosclerotic comorbidities. In patients with prior use of NOACs and no OACs, SAPT was not associated with an increased risk of in-hospital mortality. By contrast, in patients with prior use of warfarin, SAPT was associated with a higher rate of in-hospital mortality ( Figure 2 ).
For ambulatory and functional outcomes, patients with prior use of DAPT were less likely to be discharged home than those without any prior use of antiplatelet agents among patients with prior use of no OAC, but there was no difference in patients with prior use of warfarin or NOACs. When directly compared with prior use of warfarin, patients with prior use of NOACs had lower in-hospital mortality compared with patients with prior use of warfarin regardless of antiplatelet therapy, and the difference in mortality between patients with prior use of NOACs vs prior use of warfarin was numerically greater among patients with prior use of dual antiplatelet agents (32.7% vs 47.1%; ARD, −15.0% [97.5% CI, −26.3% to −3.8%]; AOR, 0.50 [97.5% CI, 0.29 to 0.86]) than among those without prior antiplatelet therapy (26.4% vs 31.7%; ARD, −5.0% [97.5% CI, −6.8% to −3.2%]; AOR, 0.77 [97.5% CI, 0.70 to 0.85]), although the P value of interaction (.07) was not statistically significant (eTable 5 in the Supplement).
Comparison of Outcomes in NOAC-vs Warfarin-Treated Patients With Therapeutic Range of INR
There was a dose-response relationship between INR and outcomes in patients with prior use of warfarin who experienced an ICH. The unadjusted in-hospital mortality rates were 25.0% for those with prior use of warfarin with (Table 3) . These findings were consistent when confined to patients without prior use of concomitant antiplatelet therapy.
Discussion
To our knowledge, this study is the largest clinical experience with anticoagulation-related ICH. Of more than 141 000 ICH hospitalizations, 10.6% of patients were receiving warfarin and 3.5% were receiving NOACs prior to ICH. While both prior use of warfarin and prior use of NOACs were associated with the increased odds of mortality compared with no prior use of OACs, patients with prior use of NOACs compared with those with prior use of warfarin were more likely to have favorable outcomes in terms of in-hospital mortality and disability. Moreover, prior use of concomitant antiplatelet therapy was associated with increased odds of in-hospital mortality among patients with preceding warfarin therapy, but such significant differences were not observed among patients with preceding NOAC therapy, likely because of the smaller sample size of patients with prior NOAC use. Prior studies have demonstrated that warfarin users were at increased risk of ICH, and warfarin-associated ICH was associated with larger hematoma volumes, 14 Two previous studies evaluated anticoagulation-related ICH and found that mortality in NOAC-treated patients was numerically lower than that in warfarin-treated patients; however, the differences were not statistically significant, which was likely due to the small number of ICH cases in the NOAC groups (n = 97 and 101). 17, 18 Other studies with a limited number of cases suggested that smaller ICH volume, lower likelihood of hematoma expansion, and better functional outcomes occurred in patients taking NOACs compared with warfarin.
19-21
Unlike previous research, the current analysis included a large contemporary cohort of ICH from 1662 US hospitals. This study found that among these patients with ICH, prior use of warfarin and prior use of NOACs were associated with increased odds of in-hospital mortality compared with spontaneous ICH among patients not taking any OAC. Nonetheless, preceding use of NOACs was associated with a decreased risk of in-hospital mortality and better in-hospital outcomes than preceding use of warfarin, and importantly, this association was consistent when patients with prior use of NOACs were compared with patients with prior use of warfarin whose INR levels were controlled within the therapeutic range. Because many of these patients should be taking OACs for prevention of thromboembolic complications, 22 these findings suggest that NOACs may be a better option than warfarin, considering the lower mortality risk among patients with ICH with prior use of NOACs. Furthermore, NOACs have been shown to be cost-effective relative to warfarin despite the assumption that outcomes after ICH would be identical regardless of OAC types. 23 The findings of this analysis further support the costeffectiveness of NOACs by showing that ICH outcomes are less severe among patients with prior use of NOACs compared with patients with prior use of warfarin. In patients receiving OACs, concomitant use of antiplatelet therapy was associated with a 3-fold increase in ICH (0.9% vs 0.3%); therefore, a large portion of patients with ICH were taking both anticoagulant and antiplatelet therapy prior to stroke in this study and that of Shireman et al. 24 Given the potential risk of hematoma expansion, concomitant use of OACs and antiplatelet therapy might affect the outcomes of ICH; however, few studies have evaluated the incremental risk of mortality and disability in patients with ICH taking both anticoagulants and antiplatelet agents, especially in the era of NOACs.
A prior meta-analysis, which was conducted before the advent of NOACs, reported higher in-hospital mortality in patients with preceding use of antiplatelet therapy. 25 Similarly, a recent report from the GWTG-Stroke registry showed that patients with prior use of multiple antiplatelet agents, but not SAPT, were at increased risk of in-hospital mortality. 26 Yet in these analyses, patients with concomitant use of OACs were excluded and the incremental risk of antiplatelet therapy in patients treated with OACs could not be evaluated.
In several clinical settings, patients are eligible for both anticoagulation and antiplatelet therapies, such as patients with atrial fibrillation who received recent percutaneous coronary intervention. Particularly in patients with atrial fibrillation, the combination of OAC and DAPT is considered required in those who require coronary stent implantation up to 6 months, depending on the individualized ischemic and bleeding risks.
27,28 Although warfarin and NOACs are recommended for the combination strategy of antiplatelet and anticoagulation therapies, 27 a recent trial comparing 3 different antithrombotic strategies (low-dose rivaroxaban plus a P2Y 12 inhibitor, very-low-dose rivaroxaban plus DAPT, and warfarin plus DAPT) demonstrated lower bleeding rates in the rivaroxaban strategies than in the warfarin strategy, with similar efficacy.
29-31
The current study found significantly increased odds of in-hospital mortality among patients with prior warfarin 
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Intracerebral Hemorrhage in Patients Receiving Oral Anticoagulants and antiplatelet therapy, whereas such differences were not observed in patients with prior NOAC treatment. Furthermore, the direct comparison between NOACs and warfarin demonstrated that the lower in-hospital mortality among patients with prior NOAC therapy was numerically more prominent among patients with prior concomitant antiplatelet therapy. While these findings are not conclusive given the relatively small of number of patients with concomitant NOAC and antiplatelet therapy, they may support the hypothesis that NOACs could be a reasonable choice with better safety profiles when combination strategy is required. The recently published Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (RE-DUAL PCI) trial also confirmed this hypothesis.
32
The major concern regarding NOACs is a lack of specific reversal agents. Immediate management is necessary for patients with life-threatening bleeding including ICH, and appropriate reversal agents should be administered. Idarucizumab, a specific antidote for dabigatran, is commercially available in the United States, 33 while a reversal agent for factor Xa inhibitors, such as andexanet alfa, has not yet been approved. 34 In this study, more than half of patients with ICH (63%) were admitted before the approval of idarucizumab, but the preceding use of NOACs was associated with lower odds of mortality and disability compared with prior use of warfarin for which an established reversal strategy could be applied. The intensity of anticoagulation is predictive of outcomes in warfarin-treated patients who experienced an ICH. An evaluation of patients with supratentorial ICH suggested that warfarin therapy increased the risk of mortality from 25.8% for patients not receiving warfarin to 52.0%, and the risk increased further with higher INR levels. 35 The result of this study was consistent with this previous finding and additionally showed that supratherapeutic warfarin was associated with the increased risk of poor neurological outcome. In clinical practice, maintaining INR within the therapeutic range could be challenging. Even in the clinical trials comparing warfarin with NOACs in terms of efficacy and safety, time in therapeutic range went from only 55.2% to 64.9%. [3] [4] [5] [6] NOACs might be a better option in broader clinical situations, given the risk of worse outcomes of ICH with supratherapeutic INR (even with therapeutic INR) and the challenge in achieving time in therapeutic range with warfarin.
Limitations
This study has several limitations. First, despite the use of a large number of characteristics to adjust for potential confounding, residual or unmeasured confounding may exist and it may be most prominent in terms of comparison with the no OAC group. Because it is not feasible to randomize patients with ICH to different antithrombotic regimens prior to ICH, our observational findings provide important clinical insights in the context of oral anticoagulation-related ICH, especially in the era of NOACs. Second, the data were obtained from hospitals participating in the GWTG-Stroke program and may not be able to be extrapolated to patients treated in hospitals outside the registry. Nonetheless, to our knowledge, GWTG-Stroke is the largest stroke registry in the United States, covering about three-fourths of the US population. Furthermore, ICH tends to be concentrated at large teaching hospitals. Given the higher representation of highvolume and academic centers in GWTG-Stroke, 36 the study population of this investigation is potentially quite representative of patients with ICH in the United States. Third, despite the large sample size, in the analysis evaluating the incremental risk of mortality and morbidity with concomitant preceding use of antiplatelet and anticoagulant Sixth, some patients were missing data on mRS at discharge (43.7%), which could skew the results for this exploratory outcome; however, it is unlikely that physicians will report ICH severity differently according to anticoagulation type prior to admission. Seventh, in our database, ICH volume, hematoma expansion, and commonly used clinical scores (eg, ICH score) 37 were not available, yet these variables are surrogate markers for predicting mortality and disability. Because harder end points, such as in-hospital death, functional outcomes represented by mRS at discharge, and discharge disposition, were evaluated in our study, assessing these surrogate markers may not provide additional insights. In addition, given that greater ICH volume, greater hematoma expansion, and higher ICH score may be caused by the preceding use of NOACs or warfarin resulting in the worse clinical outcomes, including these variables in the models would not be appropriate.
Conclusions
Among patients with ICH, prior use of NOACs or warfarin was associated with higher in-hospital mortality compared with no OACs. Prior use of NOACs, compared with prior use of warfarin, was associated with lower risk of in-hospital mortality. 
